Viking Therapeutics Q3 2026 Earnings Call and Webcast - VIKING THERAPEUTICS INC

Explicit Guidance:

• Cash Burn Rate: Management expects average company-wide cash usage of approximately $100 million per quarter moving forward, noting that specific quarters may vary higher or lower due to the current quarter's elevated spending on commercial build-out and financing timing.
• General & Administrative (G&A): G&A expenses are projected to remain fairly flat in the near term, with potential increases expected later as commercialization efforts ramp up.
• Financial Runway: Following the Q3 2026 financing ($575M raised), the company holds $960 million in cash and short-term investments (as of Sept 30, 2026), providing sufficient runway to reach key clinical milestones and support commercial launch preparations.

Business-Segment Outlook:

• VK2735 (Subcutaneous): The Phase III Vanquish I and II trials are fully enrolled and advancing on plan; first patients are expected to enter the extension periods in early 2027.
• VK2735 (Oral): The Phase III Sunrise program has initiated two studies (obesity with comorbidities; obesity + Type 2 Diabetes); dosing is once daily for 68 weeks.
• VK2735 Maintenance: A follow-up study (Part 2) is underway to evaluate oral maintenance and additional subcutaneous regimens (every other week/monthly); results expected in 2027.
• VK3019 (Amylin/CCT Receptor Agonist): The Phase I Single Ascending Dose (SAD) study is expected to complete by year-end 2026; the Multiple Ascending Dose (MAD) study is planned to initiate in the first quarter of 2027.
• Commercial Build-out: The commercial team is being expanded with hires in tech ops, CMC, supply chain, quality, and compliance to prepare for a potential launch in 2028 (estimated 2.5 years from the call date).

Market and Competitive Outlook:

• Differentiation Strategy: Management positions VK2735 as the first approved dual GLP-1/GIP agonist with an oral formulation, highlighting unique flexibility in dosing (weekly, every other week, monthly) and the ability to switch between formulations to mitigate adverse events.
• Market Dynamics: Anticipates a market expansion where initial users of oral therapies may transition to subcutaneous administration for greater weight loss as the market matures.
• Pricing & Profitability: Dose selections for the Sunrise program (up to 55 mg) and maintenance studies are calibrated to ensure high gross margins and a profitable enterprise model, avoiding higher doses that may not be economically viable.
• Competitive Response: Acknowledges competitor data (e.g., Zepbound/Amylin combos) but emphasizes VK2735's differentiated profile and the potential for a 3019+2735 combination to capture patients who cannot tolerate GLP-1s or require monotherapy.

Macro / Industry Outlook:

• Obesity Epidemic: Management views obesity prevalence as high enough to support significant site overlap and enrollment without competition issues, noting the large addressable market for both monotherapy and combination approaches.
• Regulatory Strategy: Targeting a robust data set from Vanquish extension studies to support potential label language for maintenance dosing (less frequent dosing regimens), though the exact timing of NDA inclusion vs. supplement is TBD.

Strategic Initiatives:

• Dosing Regimen Expansion: Actively developing less frequent dosing strategies (every other week, monthly) for subcutaneous VK2735 and daily oral maintenance to improve patient adherence and quality of life.
• Pipeline Diversification: Advancing VK3019 as a novel amylin/calcitonin dual agonist, with plans to evaluate it as a combination therapy with VK2735 to leverage non-overlapping mechanisms.
• Capacity & Supply: Scaling CMC, quality, and compliance functions in anticipation of commercial launch.

Risks and Headwinds to Outlook:

• Trial Completion & Data: Success of the Vanquish and Sunrise Phase III trials and the maintenance Part 2 study is required to validate efficacy and dosing flexibility; outcomes are uncertain.
• Regulatory Uncertainty: Whether maintenance data will be included in the initial NDA or require a future supplement is currently TBD; regulatory dialogue details are not disclosed.
• Development Timeline: The projected launch remains dependent on the successful completion of Phase III trials and the initiation of subsequent studies (e.g., VK3019 MAD in Q1 2027).

Management Tone on the Future:

• Confidence Level: Management expresses high confidence in the program's progress, citing "excellent tolerability" in maintenance cohorts, "no signs of plateau" in weight loss, and a solid commercial foundation.
• Strategic Focus: Tone is execution-oriented and focused on internal pipeline delivery, though they remain open to strategic in-licensing if opportunities align, preferring to maintain focus on current assets.
• Transparency: Willing to discuss commercial staffing and dosing rationale while maintaining caution on specific future efficacy projections and regulatory outcomes.

Miscellaneous:

• Titration Schedules: Vanquish studies use weekly titration; Sunrise oral titration involves 4-week blocks to reach 55 mg over 68 weeks (e.g., 60 weeks at 27.5 mg, 52 weeks at 55 mg).
• Study Overlap: Significant overlap in clinical sites between Vanquish and Sunrise programs is anticipated to facilitate enrollment.